Genentech to Present New Data on Medicines for Autoimmune Diseases and Severe Inflammatory Disorders at the 2016 ACR/ARHP Annual Meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Genentech to Present New Data on Medicines for Autoimmune Diseases and Severe Inflammatory Disorders at the 2016 ACR/ARHP Annual Meeting
November 4, 2016 8:26 AM EDT
Needham & Company reiterated a Buy rating on Rogers Corp (NYSE: ROG), and raised the price target to $75.00 (from $70.00), following the company's 3Q earnings report. ROG reported revenues of $165M and EPS of $0.95, above prior guidance for $150-160M and adjusted EPS of $0.69-0.79. Previous consensus... More
November 3, 2016 12:39 PM EDT
Genentech, a member of the Roche Group (OTC: RHHBY), announced that more than 60 abstracts featuring nine of its approved or investigational medicines will be presented during the 58th American Society of Hematology (ASH) Annual Meeting from December 3-6 in San Diego. The abstracts include more than 20 oral presentations across a broad range of medicines and combinations.
The breadth of data we are presenting at ASH this year reflects our deep commitment to people with blood diseases, said Sandra Horning, M.D., chief medical officer and head of Global Product Development. We are... More
November 2, 2016 5:45 PM EDT
Rogers (NYSE: ROG) reported Q3 EPS of $0.88, $0.20 better than the analyst estimate of $0.68. Revenue for the quarter came in at $165.3 million versus the consensus estimate of $154.02 million.
For earnings history and earnings-related data on Rogers (ROG) click here.
...
More
